Entering text into the input field will update the search result below

Pharmaceutical Company Pfizer Dividend Growth Investing Results

Apr. 05, 2021 12:53 PM ETPfizer Inc. (PFE)29 Comments
Lynn Costlow profile picture
Lynn Costlow


  • Pharmaceutical giant Pfizer and its German partner BioNTech have earned much news lately due to their successful warp speed COVID-19 vaccine development.
  • This article updates my 2016 article on the PFE holding I initiated in 2001.
  • I am committed to dividend growth investing (DGI) and started PFE acquisitions two decades ago because its dividend growth record appealed to me.
  • PFE’s long-term dividend growth has been consistent except for an unexpected one-time 50 percent dividend rate cut in 2009.
  • Despite the cut, dividend rate raises and reinvestment have boosted my PFE dividend payout growth and enabled cumulative dividends to approach my original purchase cost.

Pfizer Makes $1.95 Billion Deal With U.S. For Future COVID-19 Vaccine
Photo by Jeenah Moon/Getty Images News via Getty Images

The Acquisition History and Rationale

In 2001, I bought an initial block of 100 shares of Pfizer (NYSE:PFE), a large pharmaceutical company, for $37.50 per share. It was one of the first individual

This article was written by

Lynn Costlow profile picture
I am a retired engineering executive and a committed self-taught dividend growth investor. I am a proponent of "buy and hold" and reinvesting dividends to compound stock share count and dividend payouts. After decades of paying mutual funds to manage my retirement and taxable accounts, I now manage these funds entirely by myself and am fascinated by the never-ending learning process about investing, individual companies, their management and Mr. Market's behavior. I have seriously studied Warren Buffett and his investing approach, as well as his methods of managing Berkshire Hathaway. I have been investing in high-quality dividend growth companies since 2001. I enjoy watching dividends compound and analyzing companies that managed to survive the Financial Crisis with minimal impact on earnings and dividends.

Analyst’s Disclosure: I am/we are long PFE. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The article primarily describes a dividend growth investing experience with PFE over two decades.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.